Australian company Antisense Therapeutics announced encouraging results from its phase 2, open-label clinical trial of the company’s investigational therapy ATL1102 for treating Duchenne muscular dystrophy (DMD). The study met its primary endpoint, which was to assess the safety and tolerability of ATL1102 in patients with DMD who are non-ambulatory (unable to walk independently). After six months of weekly, subcutaneous treatment with a low dose, the drug appeared to be safe and well-tolerated in all participants with only minor side effects. Secondary endpoint results also seemed encouraging, as the drug lowered the average number of specific immune cells during the treatment period and largely improved measurements of functional capacity in seven of nine boys treated.
What do you think of this news? Do you feel hopeful about this news for DMD?
Muscular Dystrophy News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.